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Abstract 
One of the most challenging complications in trauma surgery is infection after 
fracture fixation (IFF). IFF may result in permanent functional loss or even 
amputation of the affected limb in patients who may otherwise be expected to 
achieve complete, uneventful healing. Over the past decades, the problem of implant 
related bone infections has garnered increasing attention both in the clinical as well 
as preclinical arenas; however this has primarily been focused upon prosthetic joint 
infection (PJI), rather than on IFF. Although IFF shares many similarities with PJI, 
there are numerous critical differences in many facets including prevention, diagnosis 
and treatment. Admittedly, extrapolating data from PJI research to FFI has been of 
value to the trauma surgeon, but we should also be aware of the unique challenges 
posed by IFF that may not be accounted for in the PJI literature.   
This review summarizes the clinical approaches towards the diagnosis and treatment 
of IFF with an emphasis on the unique aspects of fracture care that distinguish IFF 
from PJI. Finally, recent developments in anti-infective technologies that may be 
particularly suitable or applicable for trauma patients in the future will be briefly 
discussed.  
 
Key Words: Infection after fracture fixation, implant-related infection, infected non-
union, complications, biofilm, antibiotic therapy       
Introduction 
The operative fixation of skeletal fractures can be highly complex due to the 
unpredictable nature of the bone damage, the multitude of concomitant injuries that 
may need to be considered and the frequency of life-threatening situations in 
emergency care. One of the most feared and challenging complications in the 
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treatment of musculoskeletal trauma patients is infection after fracture fixation (IFF), 
which can delay healing, lead to permanent functional loss, or even amputation of the 
affected limb.  
Treating IFF may also result in significant socio-economic costs and can result in 
protracted recovery periods for affected patients [1]. Recent studies showed median 
costs per patient double to over 108'000 USD per patient when infected [2] with 
reported treatment success rates of only between 70 and 90% [3, 4]. The incidence 
of IFF has been tracked in numerous small-scale studies, with values from the 1980's 
and 90's indicating that the infection rate may range from as low as approximately 
1% after operative fixation of closed low-energy fractures, to more than 30% in 
complex open tibia fractures [5, 6]. Over the past decades, it appears that there has 
been a steady reduction in the overall incidence of infection [7]. However, the 
question must be asked as to whether or not we have reached a plateau on what can 
be achieved by current protocols [8]. The persistence of the problem, and the 
somewhat unsatisfactory treatment outcomes, suggests that neither prophylaxis nor 
treatment of IFF is completely effective despite best practice, and further 
improvements should be sought.  
Much of the surgical and medical treatment concepts currently applied to IFF have 
been adopted from prosthetic joint infection (PJI) treatment algorithms. Specific data, 
tailored towards the musculoskeletal trauma patient, is comparatively scarce. IFF and 
PJI do indeed have similar clinical properties, however there are important 
distinctions between the elective arthroplasty patient and the trauma patient, both in 
terms of risk of infection at the primary surgery, and in treatment options. Clearly, 
there is likely to be significant differences in the soft tissues overlying the surgical 
site: the fracture patient may have significant soft tissue damage or compromised 
vasculature secondary to the trauma, which is less common in elective arthroplasty 
patients. This vascular and soft tissue damage can impair access of the host 
defences and antibiotic therapy to the affected areas. Open fracture wounds are also 
certainly contaminated with an unknown variety and abundance of contaminating 
bacteria that are not present in elective patients. Furthermore, trauma patients may 
also require repeated visits to the OR for definitive fixation, second look, or plastic 
surgery for soft tissue flaps, which are not routine in primary arthroplasty. Amongst 
the most obvious technical differences in IFF is the presence of a fracture and the 
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need for biomechanical stability in order for it to heal. Clinical guidelines highlight the 
fact that construct stability is important not only for prevention, but also for treatment 
of IFF [9, 10]. Furthermore, in contrast to PJI, fracture fixation devices may be 
removed after osseous healing and therefore complete immediate eradication of 
infection is not always the primary goal and suppressive antibiotic therapy may be an 
option in advance of later implant removal when treatment outcome and success is 
likely to be improved. Finally, identification of infecting pathogens may be possible by 
joint puncture prior to surgical intervention in the case of PJI, however, biopsies are 
more often taken intraoperatively for IFF, which can delay or complicate diagnosis of 
IFF.  
Preclinical research studies looking into the risk and progression of bone infection 
specifically in trauma-relevant models are also scarce [11-13], and few specific 
innovations have been translated from the academic arena and made available to the 
musculoskeletal trauma surgeon [14-16]. In this review, we summarize the 
preventative, diagnostic and therapeutic guidelines for IFF with an emphasis on the 
unique aspects of fracture care that distinguish IFF from PJI. Furthermore, we 
summarize the latest preclinical and clinical research innovations regarding 
prevention and treatment of IFF.  
Definition and classification 
Definition 
Accurately estimating the impact of fracture related complications has been 
hampered by the lack of clear definitions for complications such as nonunion or 
infection. To date, there are no available standard criteria and a lack of consensus 
regarding the definition of IFF. This is in contrast to the situation for PJI, where a 
definition is available [17]. The trauma literature often cites the Centers for Disease 
Control (CDC)-guidelines for surgical site infection (SSI). The CDC definition divides 
SSIs into superficial, deep incisional and organ/space [18]. Furthermore, 
osteomyelitis is stated separately. As the fracture nor the implant taken into account, 
the complexity of an infected traumatic fracture is not completely covered by these 
guidelines. The problem becomes clear when reviewing the clinical literature. Some 
studies have cited the CDC-guidelines without a specific description of osteomyelitis 
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[19, 20]; others use these guidelines but include their own additional inclusion criteria 
such as purulent drainage or other clinical signs [21]. Perhaps due to the lack of 
suitable definitions for trauma patients, there are also authors who do not define 
infection [22] and others who provide a unique custom-made definition [23]. 
Interestingly, this issue was already mentioned by Arens et al. in 1996 [24], wherein 
the authors stated: ´It is astonishing that in all papers in which infection is mentioned, 
the term 'infection’ is not defined´. A better understanding and description of the 
definition of IFF is therefore a needed first step towards improving scientific reporting 
and evaluation of routine clinical data, as well as aid in the evaluation of novel 
prevention and treatment strategies [25].  
Classification 
Although there is a lack of clear definitions, there is a widely accepted classification 
scheme for IFF [26, 27]. Willeneger and Roth classified IFF in the 1980's according to 
the time of onset into three groups: those with an early (less than 2 weeks), delayed 
(2−10 weeks), and late onset (more than 10 weeks) infection [27]. This classification 
has been adopted widely and is important because it has an influence on treatment 
decisions made by physicians [26]. Although infections with delayed and late 
manifestations may be combined[26], a trisection of this classification seems more 
appropriate. The relative frequency of infections of each type is not available from the 
published literature, but would represent an interesting validation of the classification 
scheme should such data become available. In the following section, this 
classification will be discussed, with particular reference to onset of IFF, biofilm 
formation and, importantly for the trauma surgeon, fracture-healing status  (Figure 1). 
Early infection (< 2 weeks) 
Early IFFs are often a clinical diagnosis since the patient generally presents with 
classic signs of infection (rubor, calor, dolor, tumor and functio laesa), wound healing 
disturbances, large hematomas, and accompanying systemic signs of infection such 
as fever and lethargy. Highly virulent organisms, like Staphylococcus aureus, are 
frequent causative agents of early infection [26]. Within this timeframe, it is commonly 
considered that the causative bacteria may already have formed a biofilm, although 
this biofilm may still be in an ‘immature’ phase.  
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With regard to bone involvement and healing, preclinical models have shown that at 
one-week post-inoculation, the bone does not show signs of osteomyelitis or 
osteolysis (Figure 2), despite the presence of bacteria. Furthermore, bone healing is 
in the ‘inflammatory or soft callus stage’ [28], and so there will be no fracture stability 
at this early stage. As discussed later, these pathophysiological conditions (active 
infection without radiographic signs of fracture stability) have significant treatment 
consequences due to the importance of fracture healing for successful treatment 
outcomes. 
Delayed infection (2 – 10 weeks) 
Patients with delayed infections can present with symptoms consistent with either 
early or late infections. For example, hematomas, which may be expected in earlier 
stages, may still be present after 3 weeks, or alternatively, a fistula can also present 
itself after 9 weeks, which may be more often associated with late infections.  
There are several important distinctions from early infections. Delayed infections are 
typically due to less virulent bacteria, such as Staphylococcus epidermidis [26], and 
as the duration of infection extends, biofilms mature and become more resistant to 
antibiotic therapy and host defenses.  
In terms of fracture healing, preclinical studies show that normal bone healing takes 
up to 10 weeks [29], with a ‘hard callus stage’ that is situated between 3-16 weeks 
[28, 30]. In case of infection, this changes significantly. Experimental studies have 
shown that S. epidermidis inoculation into a fracture gap in the rat can lead to non-
union rates of 83-100% at 8 weeks [31]. Bilgili et al. could prove, in a similar 
approach, that IFF was associated with weaker callus formation [32]. These 
observations, in combination with the fact that bacterial bone invasion and 
inflammation (‘osteomyelitis’) often occur within 2 - 10 weeks (Figure 2), explain why 
treatment choices are often different compared to early onset infections where 
fracture healing may not have commenced, and bone involvement may still be 
minimal.  
Late infection (> 10 weeks)  
Many patients with late infections can present with subtle symptoms, compromised 
functionality and stress dependent pain, localized swelling and erythema or a 
draining sinus tract, mostly lacking systemic manifestation [33, 34]. In patients 
presenting with compromised functionality and stress dependent pain, infection with 
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low-virulence microorganisms should always be considered a possible cause (a 
clinically silent infection) [33]. Late, as delayed, IFF is primarily caused by micro-
organisms of low virulence like S. epidermidis [26].  
Compromised fracture healing is a frequent observation in late infections and 
although bone healing may have taken place in some cases, severe inflammation 
and osteolysis with osteomyelitis lead to instability of the osteosynthesis (Figure 2). 
Periosteal new bone formation around the periphery of the infected area produces an 
involucrum that further walls off the infection [35]. These changes often necessitate 
extensive and repeated debridements, resulting in bone defects. 
Diagnosis 
The diagnosis of IFF is challenging and based on a combination of various diagnostic 
criteria: past medical history, host physiology, clinical presentation, laboratory tests, 
imaging modalities and culturing of intraoperative tissue samples. Local signs of 
infection should be considered an IFF until proven otherwise. Signs such as a 
draining fistula from the implant or pus drainage are considered definitive signs of 
infection.  
Evaluation of host physiology    
The detailed examination of patients with a suspected IFF includes a clinical 
assessment, and complete medical history, as well as an evaluation of the host local 
and systemic risk factors. High-risk injuries including open fractures with severe soft-
tissue damage, a previous history of infection or a compromised host physiology [36]. 
Characteristics of compromised host physiology, such as chronic immune 
suppression (diabetes, malignancy, severe liver or renal disease, alcoholism), 
impairment of local vascularity and soft-tissue integument or deficiency in wound 
healing, should not only influence the risk assessment for infection, it should also 
influence treatment concepts [37]. Therefore, treating surgeons should be reluctant to 
perform complex reconstructive procedures in patients where these high-risk host 
factors are identified [33, 38].  
Laboratory examination 
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White blood cell count (WBC) with differential and neutrophil count display low 
sensitivity and specificity for diagnosing IFF [26, 39]. Persistent elevation or a 
secondary rise in C-reactive protein (CRP) can be an indicator for IFF [40, 41]. 
Microbiology 
IFF is mostly due to bacterial communities growing in protected biofilms on the 
foreign material and in necrotic bone tissue [42]. These localized grouped bacteria 
are often metabolically quiescent, which makes them difficult to identify and culture 
[43, 44]. Cultures taken from an open wound at the time of initial fracture fixation do 
not correlate with an eventual later infection and should be avoided [45, 46]. 
Similarly, swab cultures at the time of revision surgery do not reliably represent the  
pathogens in the bone [47, 48] and are therefore not recommended. In case of 
suspected infection, at least three bone biopsies should be taken close to the implant 
and in regions of macroscopically perceived infection such as necrotic bone tissue or 
non-unions [26]. If the same microorganism is cultured in at least two separate 
biopsies, it is believed to be relevant. In case of virulent species such as S. aureus or 
E. coli, a single positive biopsy may already sufficiently represent an infection [17]. If 
involvement of an adjacent joint is suspected, joint fluid for analysis (cell count, 
cultures) should be aspirated. Whenever possible, antibiotics should be avoided for 
at least 2 weeks before microbiological culturing, since this can transform specific 
bacterial species into viable but non-culturable forms [49] and cultures may therefore 
become falsely negative [50]. There is still an on-going debate about the duration of 
culture incubation: from 7 up to 14 days of incubation can be reasonable [51, 52], 
balancing the risk of missing a difficult to culture pathogen with the risk of culturing an 
irrelevant contaminant. 
If implanted hardware is removed during surgery, these should be sent to the 
microbiological laboratory for sonication and cultivation of sonication fluid, if possible.  
Sonication is believed to detach the biofilm-encased bacteria from the implant and 
disrupt the biofilms themselves, thereby rendering the bacteria amenable for 
cultivation. This method has proved to increase the yield of positive cultures, 
especially after pre-treatment with antibiotics [53-56]. 
Although culturing is still believed to be the gold standard for microbiologic 
assessment, molecular methods are increasingly being added to identify difficult to 
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culture or non-culturable bacteria. Especially after antibiotic pre-treatment, detecting 
pathogens with polymerase chain reaction (PCR) has proven to be a valuable 
complementation [57-59]. However, the high resolution and sensitivity of PCR comes 
along with the risk of false-positive results from contaminants [60, 61]. Furthermore, it 
commonly cannot distinguish between live or dead bacteria and does not provide 
broad information about susceptibility to antibiotics, except of the presence of specific 
resistance genes [62]. 
Histology 
Routine diagnostics of IFF may include histological analysis of several tissue 
samples, that were taken intra-operatively from the site of suspected infection and/or 
non-union [63]. The histological examination allows differentiation between acute and 
chronic infection, proof of necrotic bone and detection of malignancy and delivers in 
combination with microbiological analysis important clues on the presence of a bone 
infection [33].  
Imaging 
Serial radiographs are the first method of choice in complications after fracture 
fixation to gain a primary overview of the anatomy and to judge fracture healing 
status, implant positioning, possible implant failure, limb alignment and bone quality 
[64]. However, plain radiographs are not suitable to differentiate between septic and 
aseptic changes in active infections [26, 65]. In chronic infections, areas with a 
suspected bone infection may display sequestration, cortical irregularities, bone 
resorption and bone/callus formation [33, 65]. For more precise planning of the 
surgical procedure, computed tomography (CT) provides more detail about bone 
architecture to evaluate fracture pattern, new bone formation and necrotic bone as 
well as implant loosening and delivers additional evidence for infection: cortical bone 
reaction, presence of sequestration or intraosseous fistula and abscess formation in 
the adjacent soft-tissue [33, 66, 67].  
Magnetic resonance imaging (MRI) is the method of choice to evaluate soft-tissue 
involvement and gives additional information about intramedullary infection 
manifestation [39]. However in cases of IFF, metal artefacts impair correct evaluation 
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and scarring or edema in postoperative/posttraumatic bone defects may mimic an 
infection [68].  
Nuclear imaging modalities are often included in the diagnostic pathway of these type 
of infections [69, 70]. Nuclear imaging is using radioactive radiopharmaceuticals to 
visualize and trace (patho-) physiological changes, such as fracture healing, bone re-
modelling and inflammatory response to an infection. The combination of these 
functional imaging studies with morphological imaging, such as CT in one device is 
called hybrid imaging (SPECT/CT). It allows precise localization of the suspected 
infection and facilitates the discrimination between bone and soft-tissue infection [70]. 
Bone scintigraphy, usually performed with technetium-99m-diphosphonates (99mTc) 
is positive for osteomyelitis in the case of focal hyperaemia or hyperperfusion and 
focally increased bone activity [70]. Since these physiological changes are also 
involved in fracture healing, it cannot discriminate between infection and 
posttraumatic bone formation. Therefore, bone scintigraphy has limited value in the 
diagnosis of IFF [26, 39, 70]. WBC imaging, using in vitro labeled leucocytes is a 
promising technique to identify bacterial infections, but is not routinely available due 
to complex in vitro labeling [70]. 18F-fluoro-desoxy-glucose PET (FDG-PET), is very 
useful in musculoskeletal infections to visualize and precisely localize the infection 
with a high sensitivity and specificity [70]. Its role in IFF still remains inconclusive and 
has to be determined.  
Treatment 
General considerations 
The central aims of treating IFF are shown in Table 1. Remember that every case of 
IFF is to be considered as a unique case, since there is no standard procedure that 
can be routinely applied to every patient. 
In contrast to PJI, fracture fixation devices can be removed after healing has 
occurred, thereby removing the biofilm and resulting in a high chance of clearance of 
the infection. Therefore, complete eradication of infection is not always the primary 
goal. Suppressive therapy with antibiotics can be an established alternative in certain 
cases [3, 26, 71]. In order to tailor the appropriate treatment strategy, a number of 
important questions should be considered (Table 2) [1, 26, 39]. 
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Taking these considerations into account, the above-mentioned aims can be 
achieved by two main surgical principles: 
I. Irrigation, debridement and retention of the implant combined with 
antibiotic therapy. 
II. Debridement, implant removal or exchange (one or multiple stages) with 
accompanied antibiotic therapy. 
 
In very rare cases, especially in compromised hosts with serious infections, healing 
cannot be achieved and salvage procedures, such as amputation or establishment of 
a continuous fistula, may be the only treatment alternatives.  
Regardless of which of the two main principles was chosen, the treating surgeon has 
to apply the above-mentioned diagnostic tools (CRP, radiographic analysis, etc.) to 
develop a long-term treatment concept as part of a multidisciplinary team. This 
treatment concept encompasses debridement, fracture- and soft-tissue management 
and antibiotic therapy (systemic/local). Carefully considered debridement is the 
cornerstone of treatment and involves the excision of necrotic and infected (bone- 
and soft-) tissue, evaluation of the osteosynthetic construct (stability), removal of 
foreign bodies (e.g. sequesters, broken screws, sutures) and acquisition of multiple 
tissue samples for diagnostics [72]. Radical debridement should not be limited by 
concerns of creating bone or soft-tissue defects [33], one must compare debridement 
to ‘Oncologic resections’. Leaving a high concentration of pathogens (‘cancer cells’) 
in a specific surgical area, will lead to recurrence of the disease. When multiple 
operative stages are planned, these defects should be temporarily filled with a spacer 
(‘dead-space management’). Finally, an adequate soft-tissue coverage is essential. 
This often means involvement of plastic surgeons in the process, for e.g. free-flaps.  
 
 
 
 
Antibiotic treatment considerations 
Systemic antibiotic therapy 
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In general, antibiotic therapy can either be curative or suppressive. In the latter case, 
the antibiotics control the infection until the fracture is healed and the implant can be 
removed [26].  Antibiotics should always be tailored to the recovered bacteria and 
their antibiotic susceptibility pattern (see Table 3).  
After surgical debridement, an initial intravenous therapy is started to achieve a rapid 
reduction of the bacterial load at the site of infection. After approximately 2 weeks of 
intravenous therapy, a switch to oral therapy with good bioavailability is suggested 
(see Table III) [73-75]. In case of treatment with aim of cure, the total treatment 
duration is usually 6 weeks after removal of implants or 12 weeks if implants stay in 
place [26, 72]. In case of treatment with aim of suppression, duration of therapy is 
linked with the time for the fracture to stabilize/heal and should commonly be 
continued for 4-6 weeks after implant removal. This is particularly recommended in 
infections with virulent bacteria such as S. aureus or Escherichia coli in order to 
prevent or treat chronic osteomyelitis. When implants are retained, a curative 
treatment is generally only effective with a biofilm-active antibiotic, which has so far 
only been shown for rifampicin against staphylococci [76-78] and for quinolone 
against Gram-negative bacteria [79-81]. Importantly, rifampicin must always be 
combined with a second antibiotic due to otherwise rapid development of resistance. 
For the same reason rifampicin should not be started before an initial bacterial load 
reduction by surgery and antibiotic therapy has occurred, all drains are drawn and 
the wound is dry [82, 83]. For staphylococci, quinolones such as ciprofloxacin or 
levofloxacin are the best-studied and effective oral antibiotic partners to rifampicin 
[76]. Other combinations have been successfully used in orthopedic implant 
infections but are less widely studied (see options in Table 3) [84]. If bacteria are 
resistant to the mentioned biofilm-active antibiotics, they are classified as difficult to 
treat and generally cannot be eradicated by the available alternative antibiotics as 
long as the implants are retained [85]. In these cases, the surgeon should strongly 
consider implant removal. 
 
Local antibiotic therapy 
Local application of antimicrobials at the site of infection through different carriers has 
gained increasing attraction. Especially in the light of impaired blood flow to the site 
of infection and necrotic bone tissue, the advantage of achieving very high local 
concentration of antimicrobials with low systemic exposure is compelling [87]. 
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Furthermore, their carries can be an important treatment option for ‘dead-space 
management’. Nowadays, the mostly used antimicrobials are gentamicin, 
tobramycin, vancomycin and cephalosporins [88]. As a carrier, one can differentiate 
between resorbable versus non-resorbable materials. Commonly, an antibiotic 
loaded non-resorbable polymethylmethacrylate (PMMA) bone cement is applied, 
which can be introduced as beads on a string or simultaneously be used for 
mechanical stabilization as a rod or for temporary filling of large bone defects [89]. 
Nevertheless, cement may also serve as an additional surface for bacteria to attach 
to, particularly after antibiotics have been eluted. This can promote ongoing infection 
or even induce antibiotic resistance [90-93]. Another negative aspect of PMMA is that 
it needs to be removed during follow-up surgery, as it is non-resorbable. 
Furthermore, studies on the elution kinetics have shown that less than 10% of 
incorporated antibiotics will normally be released from PMMA [94]. Increasing the 
porosity of the material or mixing e.g. vancomycin with tobramycin can produce 
higher eluted doses [95, 96]. 
Resorbable materials such as calcium sulfate, which can carry a wider range of 
antibiotics than PMMA and do not necessarily need re-surgery for removal, have 
shown good first results [97-100]. As a side effect, a serous fluid pocket or prolonged 
wound secretion can develop [101]. Other degradable materials are bioactive glass, 
calcium phosphates and collagen implants. It needs to be stated that for all these 
materials data from large clinical trials is lacking.  
To date, there is no clear evidence of advantage of the addition of local antibiotic to 
systemic therapy in randomized clinical trials and no clear advantage of degradable 
versus non-degradable materials in the treatment of IFF [102-104]. Despite this, local 
antibiotics seem to lower infection rates in open fractures [105]. The antibiotics 
generally exert low local and systemic toxicity [106, 107]. Nevertheless, there are 
rare case reports of acute renal failure attributable to locally applied gentamicin [108] 
or tobramycin [109]. 
Exploring the effect of coating osteosynthetic materials with an antimicrobial is a 
matter of ongoing research. Only few have made it so far onto the market. Among 
these are a gentamicin-coated intramedullary tibia nail [16, 110] and silver-coated 
megaprostheses [111]. 
Stage-dependent surgical treatment considerations 
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Treatment of early infection 
Colonization of hardware can occur intraoperatively, and biofilm formation may 
proceeds within days, with the implant thus serving as the nidus for infection and 
complicating healing/treatment [3, 112-114]. In this early stage, biofilm formation 
seems in an immature stage, and fulminant osteomyelitis is often not yet present [29, 
115]. Only in very rare clinical situations, such as severely contaminated open 
fractures, will osteomyelitis (i.e. histological signs of inflammation of the bone/bone 
marrow) occur in this timeframe. This is why retention of the fracture fixation device is 
common practice and treatment involves antibiotic therapy and tissue debridement. 
Experimental studies in the rat have shown that callus formation could be observed 
despite retention of the implant [32]. Retaining an implant in early stages is tempting 
because hardware removal would complicate the management of an unhealed 
fracture, especially in complex articular fractures. However, retention of the implant is 
only reasonable if sufficient irrigation and debridement of the implant/surgical site can 
be carried out, if the osteosynthesis construct is stable, and antibiotic therapy is 
appropriate [72, 116]. The importance of implant stability was already outlined by 
earlier research from Rittmann and Perren in experimental studies in sheep, which 
showed the positive effects of stability on fracture healing in infection [9]. 
Furthermore, stability has a much more profound influence than that of the chosen 
implant material (i.e. different metal alloys) [117, 118] 
In early infections, consolidation can be achieved despite the presence of an 
infection, as long as the osteosynthesis construct remains stable [9, 119]. If stability 
is not granted and the implant cannot be debrided properly, e.g. in intramedullary 
nails, hardware exchange should be considered [36]. Debridement also includes 
careful revision of hematomas, since they are a suitable growth medium for bacteria 
[26]. Subsequently, a 12-week course of antibiotic therapy with retained implants or 
up to 6 weeks after implant removal should follow the debridement [26, 78, 120]. 
Since debridement reduces the bacterial load and may clear an immature biofilm, 
additive systemic antibiotics will treat the remainder of the infection. Once the 
fracture has healed, it is strongly recommended to remove the implant to reduce the 
risk of a recurrent infection [119]. Berkes et al. investigated osseous union in patients 
who developed an infection within 6 weeks after the operative fracture fixation and 
that were treated with debridement, antibiotics and hardware retention. Fracture 
healing could only be achieved in 71% of the patients, whereas an open fracture and 
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the presence of an intramedullary nail were predictors for treatment failure [3]. 
Rightmire et al. performed a similar approach in infections within 16 weeks after 
osteosynthesis and reported successful union in 68%, although in 38% of the 
patients with successful bone healing, hardware had to be removed for persistent 
infection after union and therefore only 49% of the original study group achieved 
healing and was free of infection after six months [119]. These findings support the 
fact that the approach of debridement and retention is only promising in an early time 
frame after fracture fixation to achieve union and long term absence of infection.  
In the majority of early infections retention and antibiotic therapy is the best option 
[26], but there are indications where exchanging the implant should be taken into 
account [26, 39, 119]. The factors are listed in Table IV. These factors should be 
interpreted as suggestions, rather than as definite decision criteria.  
Treatment of delayed infection 
Delayed infections, ranging from 3 to 10 weeks are a grey area in which decision 
making regarding the right treatment option is more difficult than in early or late onset 
infections. It is important to understand that the classification we use (Figure 1) is a 
continuum, which means that in the early stages of this phase, implant retention 
could still be considered, whilst at the later stages, this would be more clearly 
contraindicated.  
In the presence of above-mentioned criteria (Table IV), and with increasing duration 
of symptoms or delay in diagnosis, the decision should tend towards implant 
exchange. As explained above, the biofilm develops (matures) over time and signs of 
osteomyelitis are increasingly observed (Figure 2), which means that treating these 
types of infection often demands for radical debridement and implant exchange. An 
important consideration in delayed infection is the evaluation of fracture consolidation 
by imaging studies and during surgery. If callus formation is visible and bone healing 
has progressed sufficiently to provide stability, debridement and implant removal can 
be the best choice.  
The main principles of debridement and implant removal/exchange in one or multiple 
stages are outlined in the subsection “Late infections”. 
Treatment of late infection 
In the following section we summarize three different scenarios: clinically suspected 
infection with full bone consolidation, clinically suspected infection without full bone 
 16 
consolidation, and non-union lacking clinical signs of infection. The first two scenarios 
will be discussed together. 
Clinically suspected infection with and without full consolidation 
As mentioned previously this classification of IFF is a continuum (Figure 1). Although 
this means that there is no red line separating late and delayed infections, it has to 
be taken into account that after 10 weeks (Figure 1), inflammation, fibrous 
encapsulation and osteolysis often lead to instability of the osteosynthesic construct, 
potentially resulting in delayed or non-union [29]. Furthermore, fibrous encapsulation 
of the infected area acts as a barrier around sequesters and devitalized bone.  
Clinically suspected late infection necessitates an extensive debridement with 
possible creation of bone and soft-tissue defects. The surgical treatment concept 
therefore has to include a multidisciplinary approach (trauma and plastic surgeon). 
Staged procedures may often be required, depending upon the extent of infection, 
the degree of stability, and the condition of the patient (host physiology). 
The most important considerations in late infections with, and without, consolidation 
of the fracture are: removal of the remaining fracture fixation devices/foreign bodies; 
radical debridement of all involved bone (sequesters) and soft tissue; long-term 
antimicrobial therapy (normally 6 weeks of antibiotics and up to 12 weeks if a lot of 
necrosis is present) and reconstruction of the soft tissue envelope [121].  
In both clinical scenarios, preoperative imaging studies, such as CT, MRI and nuclear 
imaging modalities are helpful to plan the resection margins including safety zones. 
The operating surgeon should be aware that resection lines should be re-evaluated 
during surgery, since transition from necrotic to vital bone is not always obvious from 
preoperative imaging. Necrotic, non-bleeding bone is removed with a chisel or high-
speed burr and represents one of the most critical steps in surgery. Intramedullary 
infection manifestations require debridement of the intramedullary canal using a 
classic reamer or a Reamer – Irrigator – Aspirator (RIA, DepuySynthes; Johnson & 
Johnson Co. Inc., New Brunswick, NJ, USA) system [121, 122].  
If possible, stability of the bone should be preserved, although in certain cases where 
extensive debridement leads to instability, especially when fracture consolidation did 
not take place, external fixation and later reconstruction are necessary. External 
fixation can be a temporary or even definitive solution (i.e. bone transport). As 
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mentioned before, the use of spacers can be important in these cases, not only for 
dead-space management but also for local antibiotic therapy.  
Non-union lacking clinical signs of infection 
In this section it will not be our goal to discuss the treatment of non-union in general. 
It seems appropriate although to start with an issue similar to the one we described 
for IFF, namely that the definition of non-union is still arbitrary [123]. It has to be 
stated that recent literature starts to accept the US Food and Drug Administration 
(FDA) guidelines, which defines non-union as a fractured bone that has not 
completely healed within 9 months of injury and that has not shown progression 
toward healing over the past 3 consecutive months on serial radiographs [124].  
Infected non-union is an underestimated problem. Gille et al. examined culture 
negative samples of 23 patients with non-union and reported the presence of 
bacterial RNA following analysis with PCR in two patients (8.7%) [125]. Palmer et al. 
analyzed 34 samples obtained from patients with non-union [126]. Although eight 
samples had a positive conventional culture, only four of 34 cases were negative 
following analysis of bacterial DNA using a combination of Ibis molecular diagnostics 
and fluorescence in situ hybridization techniques. The benefit of utilizing molecular 
based techniques could be very important, as distinguishing between septic and 
aseptic non-union is essential for determining the course of treatment [127]. In case 
of a longstanding therapy-resistant non-union, an infection should be suspected. If 
cultures are negative in these patients, as mentioned earlier, PCR could be a future 
solution. 
The problem with this type of infection is that the diagnosis often follows the surgical 
intervention. It is clear that if there is a suspicion during surgery, an extensive 
surgical debridement should be performed, as for the previously mentioned late-
onset infections. Planning a second stage procedure with removal of all internal 
fixation material (for sonication) and awaiting the results from cultures, should be 
considered. Furthermore, the use of spacers with local antibiotics (i.e. PMMA) is 
often a good additive treatment if there is a suspicion of infection during surgery. 
Solely exchanging the implant doesn’t have good results in cases of infection as was 
recently described by Tsang et al. for infected non-union of the tibia [128]. 
In a second stage, when the infection has been treated, bone grafting (i.e. Masquelet 
or induced-membrane technique) could for example be considered. In case of a 
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Masquelet procedure, the surgeon should be sure that there is no remaining 
infection, as a recent experimental study by Seebach et al. showed this can be 
worsened by the introduction of mesenchymal stromal stem cells [129]. Of course, 
definitive treatment with external fixation (i.e. bone transport) can also be considered 
[128]. 
Table 5 summarizes the considerations a surgeon should make when treating an 
infected non-union. 
Future directives  
Infection complicates a significant minority of patients after osteosynthesis, and so 
improvements in both prevention and treatment will be required to achieve better 
patient care in the coming decades. Such improvements may range from better-
defined and controlled peri-operative antibiotic prophylaxis, to more rapid and 
specific diagnostics of even sub-acute infection, to increased availability of 
antimicrobial functionalized medical devices or bone void fillers and graft material.  
Preclinical studies occupy an important junction in the assessment of such novel 
interventions, as this is the stage where new or improved interventions are assessed 
in a controlled environment prior to patient trials and full clinical implementation [130, 
131]. Numerous in vivo models of infection have been described in the literature, 
however, those that model the clinical situation as closely as possible are considered 
to provide the most robust evaluation of efficacy [132]. In the case of infection after 
osteosynthesis, models that incorporate bone infection associated with a functioning 
implant (i.e. actually fixing a surgically induced fracture/osteotomy) achieve this goal 
[29].  
Research and development has focused more on preventative rather than treatment 
strategies, as preventative strategies are considered more likely to have greater 
overall impact on healthcare costs and patient outcomes. New approaches to 
improve prevention of infection after osteosynthesis have primarily focused on local 
delivery of antibacterial compounds from specialized biomaterials formulated as 
coatings on devices [14, 16] or as additives in bone void fillers such as bone cement 
[133] or bacteriostatic bone substitute materials [134].  
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Currently, there is to our knowledge, only one antibiotic coated trauma implant that 
was available on the market, which has been found to effectively prevent infection in 
even complicated cases with high risk of infection [14, 16]. In future, more 
antibacterial functionalized implants are likely to come to market, offering competing, 
though ultimately quite similar technologies (release of conventional antibiotics or 
silver). Development and clinical implementation of antimicrobial devices in trauma 
surgery is both a scientific and economic challenge due to the complexities of the 
cost benefit equation for clinical studies and subsequent clinical uptake. For this 
reason, in the future, good cost analyses are necessary to further emphasize the 
problem of IFF. 
Looking further ahead to a scenario where antibiotic resistance in commonly 
encountered pathogens may increase, antibiotic loaded devices may become 
contraindicated, at least in hospitals with high endemic rates of pathogens resistant 
to the antibiotics within the implants. In this regard, silver has maintained its position 
as an antimicrobial for medical devices due to low resistance rates in clinical isolates. 
Antimicrobial peptides (AMP’s) are also emerging as possible antimicrobials that do 
not induce resistance within pathogens after exposure [135]. At the present time, 
AMPs have been limited to topical applications, though research strategies for 
implant functionalization have continued to emerge [136], and may yet prove a critical 
support in the face of antibiotic resistance.  
Finally, hydrogels have recently emerged as promising vehicles for antibiotic delivery 
into trauma wounds [88]. Recently, early phase clinical studies have been described 
whereby antibiotic loaded hydrogels have been applied to patients during 
osteosynthesis [137]. These hydrogels offer the benefit of ease of application to 
potentially complex wounds and may cover both the implant surface and the 
surrounding tissues. Coatings or bone void fillers, in contrast, may leach antibiotics 
from the surface to the surrounding tissues, but the surgical field may extend 
significantly beyond the peri-implant space. Hydrogels, on the other hand, can be 
applied through the wound site due to their viscous yet flowing nature [138]. It 
remains to be seen if such hydrogels progress to routine clinical implementation, but 
at the current time, they offer an attractive option for antibacterial delivery to trauma 
wounds.  
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Summary   
One of the most challenging complications in trauma surgery is the development of 
IFF. The consequences for patients and healthcare systems regarding this 
complication are severe. Despite modern advances, implant-related infection remains 
a problem in fracture care. This article gives an overview of current standpoints 
regarding diagnosis and treatment of this serious complication. Further clinical and 
translational research is necessary to improve the outcome of this specific patient 
population. 
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